Business Wire

DE-QPS-HOLDINGS

26.6.2024 21:00:28 CEST | Business Wire | Press release

Share
QPS Announces New Laboratory Services for Clinical Trials and Cell Therapy Development

QPS, a leading global contract research organization (CRO), is pleased to announce new laboratory services capabilities. The central laboratory, leukopak cell therapy facility, and enhanced PBMC capabilities will complement existing bioanalysis, translational medicine and peripheral blood mononuclear cell (PMBC) laboratories and extend the current QPS full-service global CRO offerings.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240626261072/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

QPS Missouri, a division of QPS Holdings, LLC, a global Contract Research Organization. QPS Missouri conducts Phase I-IV clinical trials and houses central lab, safety lab, PBMC and cell production services in Springfield, Missouri. (Photo: Business Wire)

QPS now offers clinical trial sample analysis services and leukopak cell therapy products from its newly expanded clinical trials unit conveniently located in Springfield, Missouri. In addition, QPS has also expanded PBMC service offerings from its Miami, Florida location into its Springfield, Missouri laboratories. The new facilities are housed with an existing clinical (safety) laboratory, a modern self-contained pharmacy, and dedicated space to build and ship clinical trial kits.

The modern central laboratory for sample analysis complements the existing on-site safety laboratory, equipped with the most up-to-date technologies for chemistry, urinalysis, serology, coagulation, and hematology testing. These capabilities, designed to monitor subject safety during ongoing clinical trials, will remain as core services for QPS in-house clinical trials.

The new leukopak products collection and processing facility is designed to meet the exponential growing demand for blood products to support cell therapy research and QPS is ideally placed to provide this service. QPS Missouri has a database of over 35,000 potential study participants, who can be contacted as potential blood donors for leukopak products.

“There is significant unmet demand in this rapidly growing area of cell therapy products, which represents a tremendous opportunity for QPS. Over 3,000 cell and gene therapy programs are currently in progress representing a 20% increase over the past five years. These programs require leukopak products to move forward, and as a result this market is forecasted to grow by a CAGR of more than 8% over the next six years,” said Benjamin Chien, Chairman, President and CEO of QPS.

The enhanced PBMC services include a new PBMC processing lab at the Springfield location, complementing the existing lab at QPS Miami in Miami, Florida. This new lab will support a current unmet need for PBMC processing in the midwestern USA. PBMC sample analysis is a time-consuming process, typically required in vaccine trials, and it is best done in a lab adjacent to the clinical trial unit. QPS is uniquely positioned to offer this service.

“These new facilities, services and products extend our full service CRO capabilities, putting QPS in a position to offer clients comprehensive clinical research services in one location. The central lab, PBMC lab, and the leukopack facility complement and enhance our current 240 bed clinical trials unit, safety laboratory, modern self-contained pharmacy, and clinical trial kit production facility,” said Brendon Bourg, Vice President, Early Phase Clinical and Head of Administration at QPS Missouri.

ABOUT QPS HOLDINGS, LLC

QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,100+ employees in the US, Europe, and Asia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, and turnkey laboratories and facilities. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240626261072/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Miro Announces Asia Hub in Singapore to Accelerate Growth Across the Region and Bring AI Collaboration to New Markets17.3.2026 02:00:00 CET | Press release

AI Innovation Workspace perfectly placed to help organisations maximise AI investment and accelerate innovation Miro®, the AI Innovation Workspace for teams, today announced plans to expand its operations in Asia, supporting organisations across the region in their AI transformation journey. Miro is investing in people, resources, and infrastructure as it targets growth in key markets, including Singapore, India, South Korea, and other Southeast Asia countries. As the global innovation centre of gravity shifts toward Asia – where R&D spending reached 45% of global investment in 2024 – the organisations leading this charge need tools and platforms built for the complexity and pace of modern innovation and collaboration. Miro's AI-powered innovation workspace is uniquely positioned to support this moment. Miro gives organisations the shared context layer they need to move from insight to execution faster than ever before. For Asia's most ambitious innovators, where speed-to-market and cr

IQM and Zurich Instruments Launch Real-Time Quantum Error Correction Demonstrator with NVIDIA NVQLink16.3.2026 22:24:00 CET | Press release

The demonstrator being built in this project delivers a clear path toward scalable and fault-tolerant quantum computers. The joint project integrates IQM’s superconducting quantum processor, Zurich Instruments’ ZQCS Quantum Control System, with the NVIDIA NVQLink platform to enable real-time error correction. This initiative establishes a foundation for standardized enterprise-ready quantum systems, and datacenter deployment. Today, IQM Quantum Computers and Zurich Instruments announce a joint project to build and operate a real-time quantum error correction (QEC) demonstrator, enabled by the NVIDIA NVQLink platform. This project marks a significant milestone toward scalable and fault-tolerant quantum computing designed for enterprise and datacenter deployment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316511715/en/ IQM and Zurich Instruments launch real-time quantum error correction demonstrator with NVIDIA NVQLink

Kinaxis Advances Large-Scale Supply Chain Optimization with NVIDIA AI16.3.2026 21:30:00 CET | Press release

Achieves up to 12X faster end-to-end planning performance in large-scale enterprise models Kinaxis® Inc. (TSX: KXS), a global leader in supply chain orchestration, today announced a new milestone in advancing large-scale supply chain optimization within the Kinaxis Maestro™ platform. Maestro already delivers high-performance optimization across complex global supply chains, and Kinaxis is now extending that leadership by leveraging GPU acceleration powered by NVIDIA cuOpt™ and NVIDIA AI infrastructure. As supply chains grow in scale and complexity, planning models must reconcile tens of millions of variables across extended time horizons and multiple planning levels. As model size expands, the number of potential decisions can scale into billions, dramatically increasing computational needs. Organizations are no longer constrained by insight alone. They are constrained by how quickly they can iterate. In testing on a large-scale semiconductor planning model with nearly 50 million decis

Lattice Joins NVIDIA Halos Ecosystem to Advance Safety for Physical AI with Holoscan Sensor Bridge16.3.2026 21:30:00 CET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced it has joined the NVIDIA Halos AI Systems Inspection Lab ecosystem, the first ANSI National Accreditation Board (ANAB) accredited inspection lab for AI-driven physical systems. Announced at the NVIDIA GTC 2026, Lattice will engage with NVIDIA and other Halos ecosystem members to build Halos-certified Holoscan Sensor Bridge-based designs for physical AI and to help shape best practices as the industry evolves. “Physical AI is rapidly moving from controlled environments into the real world, where safety, reliability, and trust are paramount,” said Raemin Wang, Vice President, Segment Marketing, Lattice Semiconductor. “Through this collaboration, Lattice looks forward to contributing our expertise in low power FPGAs and award-winning solution stacks to enable scalable, trusted physical AI systems across robotics, industrial automation, and autonomous applications.” NVIDIA Halos is a comprehensive full

Lenovo Brings Production-Scale AI to Global Sports: Enhancing Fan Experience, Driving Revenue Growth, Boosting Performance, and Improving Operational Efficiency with NVIDIA16.3.2026 21:30:00 CET | Press release

Multiyear collaboration introduces new solutions spanning Sports Intelligence, Operations, and Media & Content. At NVIDIA GTC today, Lenovo (HKSE: 992) (ADR: LNVGY) announced an expanded multiyear collaboration with NVIDIA to help the global sports industry deploy production-scale AI across mission-critical environments, transforming live data into revenue growth, operational resilience, and real-time decision advantage. The global sports technology market is projected to grow from $23 billion in 2025 to more than $60 billion by 2030. Global sports events represent some of the most complex and demanding operating environments in any industry, combining unprecedented scale, technical sophistication, and public visibility. These events engage billions of viewers worldwide, generate and process petabytes of data in real time, and require highly coordinated, distributed operations across multiple countries, all within a context where reliability, resilience, and uninterrupted performance a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye